Leukemias

The integration of the leading leukemia trial groups across Europe will enable the conduction of cooperative trials even on rare subentities of the leukemias and related syndromes. By the use of standardized data sets and common guidelines for the conduction of phase I/II trials, trial quality will be of high standards and the outcomes will be comparable across Europe. Through the transparency and visibility of the clinical trials platform and the availability of large patient numbers, the transition time from drug discovery to its application at the bedside will be significantly shortened. The network will encourage participation in trials and acceptance of clinical research.